The dosing of the first participant marks a significant milestone for Tonix as it explores the therapeutic potential of TNX-1900. Previous animal studies have indicated that intranasal oxytocin can block the release of calcitonin gene-related peptide (CGRP), a key player in migraine pathophysiology. This mechanism is distinct from existing migraine treatments, which primarily target CGRP pathways. The study will utilize Laser Speckle Contrast Imaging (LSCI) to measure the forehead skin blood flow response to capsaicin and electrical stimulation, providing real-time data on the drug's efficacy.
Tonix's CEO, Dr. Seth Lederman, expressed excitement about the collaboration with Dr. Maassen van den Brink, emphasizing the potential of TNX-1900 to address unmet needs in migraine treatment. He noted that while several CGRP inhibitors are currently available, TNX-1900's unique mechanism could offer a new therapeutic option for patients suffering from migraines and related conditions. The results of this study will be crucial in guiding the future development of TNX-1900 as a non-opioid treatment option.
As the study progresses, Tonix aims to gather data that could support the advancement of TNX-1900 through clinical trials and potentially into the market, providing hope for millions of individuals affected by migraines and craniofacial pain.
